Evidence map›Paper›PMID 42109726›Full record

ArticleFrontiers in endocrinology2026

Roundup

Izabela Fernanda Dal' Bó, Natássia Elena Bufalo, Valdemar Máximo, Laura Sterian Ward

Abstract readComparative Study
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Izabela Fernanda Dal' BóLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Natássia Elena BufaloLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Valdemar MáximoInstitute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.
Laura Sterian WardLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glyphosate-based herbicides (GBHs), such as Roundup®, are ubiquitous environmental contaminants with emerging endocrine-disrupting properties. Based on previous findings of non-monotonic effects in thyroid models, this study investigated lineage-dependent cytotoxic and proliferative responses to Roundup® in thyroid cells with different cytogenic profiles. Methods: Human papillary carcinoma (BCPAP, BRAFV600E) and anaplastic carcinoma (8505C) cells were exposed to Roundup® Original DI (6.5-6500 µg/L) for 24 and 48 hours. Cell viability was assessed using trypan blue exclusion and CCK-8 assays, and proliferation was measured by BrdU incorporation. The data were integrated with previous results from normal (Nthy-ori 3-1) and papillary (TPC-1) cell lines for comparative analysis. Results: Exposure to Roundup® induced specific effects for each cell type. The BCPAP cell line demonstrated significant sensitivity, with reduced viability and sustained proliferative stimulation at low concentrations. In contrast, anaplastic 8505C cells proved to be highly resistant, exhibiting transient biphasic proliferation and recovery of viability even at high doses. A consolidated analysis established a clear hierarchy of sensitivity: TPC-1 > BCPAP > Nthy-ori3-1 > 8505C, revealing that papillary thyroid carcinoma cells are the most vulnerable. Crucially, a concentration of 65 µg/L, which is below current regulatory limits, triggered proliferative responses in all cell models. Discussion: These results suggest that Roundup® is a potent endocrine disruptor that exerts mutation-specific proliferative effects on thyroid cancer cells. Consistent growth stimulation at low, environmentally relevant doses suggests a potential tumor-promoting role, particularly in papillary carcinomas driven by the MAPK pathway. This evidence reinforces the need to revise risk assessments of GBHs (subcutaneous hypothyroidism) to take into account endocrine disruption and the potential for cancer progression beyond traditional toxicity.

Indexed as

Cell ProliferationGlycineHerbicidesThyroid Cancer, PapillaryThyroid NeoplasmsCell Line, TumorCell SurvivalEndocrine DisruptorsGlyphosateHumansEndocrine DisruptorsGlycineGlyphosateHerbicidescytotoxicityendocrine disruptorglyphosatepesticideproliferationthyroid

Identifiers

PMID42109726
PMCPMC13149085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.